Wilmink, Michael — Insider Profile

Insider Profile

Wilmink, Michael

🔒 Follow — get an alert on any new filing

$EPRX

Companies Filed At

Open-Market Buys (2yr)

$18K

Buy Value (2yr, open-market)

Mar 09, 2026

Most Recent Trade

Credibility
Score

33%

Hit Rate

-3.4%

Avg 90d Return

-7.8%

Median 90d Return

Evaluated Trades

+28.4%

Best Trade

-39.3%

Worst Trade

Hit rate and returns are based on 6 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.

Cross-Company Track Record

25%

Hit Rate · 90d

-14.8%

Median Alpha · 90d

Closed Buys Evaluated

25%

Beat XIU

All-insider base rate: 59% hit rate · +1.3% mean alpha (n=11504)

size concentrated

Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.

Research 4 closed buys with individual return outcomes available on the Research plan.

Date	Company	Role	Nature	Dir.	Shares	Price	Value	Score
Mar 09, 2026	$EPRX Eupraxia Pharmaceuticals	—	Expiry	Sell	1,525	$11.20	$17K	62
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	10,000	$8.63	$86K	62
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	10,000	$8.63	$86K	62
Nov 02, 2025	$EPRX Eupraxia Pharmaceuticals	—	Expiry	Sell	12,500	$8.00	$100K	62
Sep 24, 2025	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	3,363	$5.50	$18K	62
Mar 31, 2025	$EPRX Eupraxia Pharmaceuticals	—	Expiry	Sell	25,000	$8.00	$200K	62
Mar 25, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	45,000	$5.14	$231K	62
Jun 11, 2024	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	800	$2.81	$2K	62
May 13, 2024	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	45,000	$3.96	$178K	62
May 10, 2024	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	640	$3.00	$2K	62
Aug 18, 2023	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Sell	2,857	$7.00	$20K	62
Mar 09, 2021	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	30,000	$8.00	$240K	62

Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.